Research map: Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments

Back to the article

Papers in this map

  1. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders · Dean M. Wingerchuk · 2015 · 4672 citations · Cited by this paper
  2. Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments · Philippe‐Antoine Bilodeau · 2026 · 2 citations · Cites this paper
  3. miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis · 2026 · Related
  4. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study · Laurent Beaugerie · 2009 · 1112 citations · Cited by this paper
  5. Patient-reported outcomes in Chinese patients with AQP4-IgG–positive neuromyelitis optica spectrum disorder on inebilizumab therapy: a cross-sectional study · Hexiang Yin · 2026 · Cites this paper
  6. Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum Disorder · 2026 · Related
  7. Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder · Sean Joseph Pittock · 2019 · 879 citations · Cited by this paper
  8. Insufficient mycophenolate mofetil maintenance dosage increases the relapse risk in neuromyelitis optica spectrum disorders · Xingyue Zhou · 2026 · Cites this paper
  9. Fulminant Amyloid β–Related Angiitis With Herniation and Rapid Response to Tocilizumab · 2026 · Related
  10. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial · Bruce Cree · 2019 · 744 citations · Cited by this paper
  11. Executive Summary of the Malaysian consensus statements for the diagnosis and management of neuromyelitis optica spectrum disorder (NMOSD) · Shanthi Viswanathan · 2026 · Cites this paper
  12. Double-Negative Neuromyelitis Optica Spectrum Disorder · 2026 · Related
  13. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder · Takashi Yamamura · 2019 · 666 citations · Cited by this paper
  14. Inebilizumab for neuromyelitis optica spectrum disorder: a systematic review · Bruna Carolina de Araújo · 2026 · Cites this paper
  15. Vestibular and Ocular Motor Phenotype in a Case of Paraneoplastic Autoimmune Kelch-Like Protein-11 Encephalitis · 2026 · Related
  16. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial · Masayuki Tahara · 2020 · 382 citations · Cited by this paper
  17. Patient education for neuromyelitis optica spectrum disorder using large language models: combining expert assessment and real-world patient interaction · Chen Li · 2026 · Cites this paper
  18. Kappa Free Light Chain for Diagnosis and Neurofilament Light Chain for Prognosis in Autoimmune Encephalitis · 2026 · Related
  19. Neuromyelitis optica: clinical features, immunopathogenesis and treatment · Sven Jarius · 2014 · 345 citations · Cited by this paper
  20. Comparative effectiveness of inebilizumab versus conventional immunotherapies in AQP4-IgG-positive NMOSD: a prospective cohort study with time-varying treatment effects · Wenjuan Huang · 2026 · Cites this paper
  21. Integrin β1 Demarks Precursors of Brain-Residing Antibody-Secreting Cells in Multiple Sclerosis · 2026 · Related
  22. A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder · Su‐Hyun Kim · 2013 · 325 citations · Cited by this paper
  23. PROFILE OF MENTAL STATES IN FEMALE PATIENTS WITH ALOPECIA ACROSS THE CONTINUUM OF MENTAL MALADAPTATION · Maryana Chemerys · 2026 · Cites this paper
  24. Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy · 2026 · Related
  25. Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica · Maureen A. Mealy · 2014 · 305 citations · Cited by this paper
  26. Aquaporin‐4 Antibodies ( NMO ‐ IgG ) as a Serological Marker of Neuromyelitis Optica: A Critical Review of the Literature · Sven Jarius · 2013 · 255 citations · Cited by this paper
  27. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis · Sven Jarius · 2023 · 233 citations · Cited by this paper
  28. Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder · Sean Joseph Pittock · 2023 · 212 citations · Cited by this paper
  29. Aquaporin-4 autoimmunity · Αναστασία Ζεκερίδου · 2015 · 204 citations · Cited by this paper
  30. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial · Zahra Nikoo · 2017 · 194 citations · Cited by this paper
  31. An overview of platform trials with a checklist for clinical readers · Jay Park · 2020 · 143 citations · Cited by this paper
  32. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease · Paula V. Barreras · 2022 · 119 citations · Cited by this paper
  33. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK · Karen O’Connell · 2020 · 109 citations · Cited by this paper
  34. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders · Andrea Marcinnò · 2018 · 84 citations · Cited by this paper
  35. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial · Mary R. Rensel · 2021 · 83 citations · Cited by this paper
  36. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis · Adrian Isidoro Espiritu · 2019 · 69 citations · Cited by this paper
  37. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar · Takashi Yamamura · 2022 · 64 citations · Cited by this paper
  38. Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated Diseases · Alexandre Avouac · 2021 · 41 citations · Cited by this paper
  39. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder · Dean M. Wingerchuk · 2021 · 37 citations · Cited by this paper

Source: OpenAlex (CC0)